Clinical evaluation of T-2588 on respiratory tract infections

Tsuneko Yamaguchi, Kenya Hiura, Yoichi Nakanishi, Osamu Katoh, Hozumi Yamada

Research output: Contribution to journalArticle

Abstract

T-2588 is a new cephem antibiotic with a broad spectrum of antibacterial activity. We performed the following clinical evaluation of T-2588 on 18 patients with respiratory tract infections including 10 cases of pneumonia, 5 of exacerbation of bronchiectasis, 2 of acute bronchitis and one of exacerbation of chronic bronchitis. Clinical responses were excellent in 8 cases, good in 9 and poor in one. T-2588 also showed the excellent in vitro antimicrobacterial activity against the clinical isolates including 5 strains of Haemophilusk influenzae, 3 strains of Streptococcus pneumoniae, each one strain of Klebsiella pneumoniae and Providencia rettgeri. The side effect was found in one case ; hypertransaminasemia. It was mild and disappeared spontaneously. From the above results, it was considered that T-2588 would be expected to be useful for the treatment of patients with respiratory tract infections.

Original languageEnglish
Pages (from-to)515-520
Number of pages6
JournalChemotherapy
Volume34
DOIs
Publication statusPublished - Jan 1 1986

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Clinical evaluation of T-2588 on respiratory tract infections'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, T., Hiura, K., Nakanishi, Y., Katoh, O., & Yamada, H. (1986). Clinical evaluation of T-2588 on respiratory tract infections. Chemotherapy, 34, 515-520. https://doi.org/10.11250/chemotherapy1953.34.Supplement2_515